Besidesm Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

M Ventures, the strategic, corporate venture capital arm of Merck KGgA, continues to fund iOmx Therapeutics AG, a company developing cancer therapeutics based on next generation immune checkpoint targets.

New zealand generalNew zealandPhilipp beckhoveNisit khandelwalGerman cancer research centreAthos service gmbAthos service gmbhBesidesm venturesWellington partnersBio developmentsCheckpoint inhibitorMerck kgaa